Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC
Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of...
Saved in:
Published in | BMC medical genomics Vol. 12; no. 1; pp. 67 - 12 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
22.05.2019
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research.
In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction.
In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs.
We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. |
---|---|
AbstractList | Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research.BACKGROUNDChemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research.In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction.METHODSIn this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction.In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs.RESULTSIn total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs.We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs.CONCLUSIONSWe screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. Methods In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. Results In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. Conclusions We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. Keywords: Small cell lung cancer, Chemoresistance, Super enhancer Abstract Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. Methods In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. Results In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. Conclusions We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE) has an important role in tumor evolution. The functions of SEs, a key class of noncoding DNA cis-regulatory elements, have been the subject of many recent studies in the field of cancer research. Methods In this study, using chromatin immunoprecipitation-sequencing and RNA-sequencing (RNA-seq), we aimed to identify SEs associated with chemoresistance from H69AR cells. Through integrated bioinformatics analysis of the MEME chip, we predicted the master transcriptional factors (TFs) binding to SE sites and verified the relationships between TFs of SEs and drug resistance by RNA interference, cell counting kit 8 assays, quantitative real-time reverse transcription polymerase chain reaction. Results In total, 108 SEs were screened from H69AR cells. When combining this analysis with RNA-seq data, 45 SEs were suggested to be closely related to drug resistance. Then, 12 master TFs were predicted to localize to regions of those SEs. Subsequently, we selected forkhead box P1 (FOXP1), interferon regulatory factor 1 (IRF1), and specificity protein 1 (SP1) to authenticate the functional relationships of master TFs with chemoresistance via SEs. Conclusions We screened out SEs involved with drug resistance and evaluated the functions of FOXP1, IRF1, and SP1 in chemoresistance. Our findings established a large group of SEs associated with drug resistance in small cell lung cancer, revealed the drug resistance mechanisms of SEs, and provided insights into the clinical applications of SEs. |
ArticleNumber | 67 |
Audience | Academic |
Author | Yang, Yunchu Fang, Shun Guo, Linlang Wu, Jingfang Chen, Size Li, Man Zou, Qingqing Liang, Shumei Bao, Jiarong |
Author_xml | – sequence: 1 givenname: Jiarong surname: Bao fullname: Bao, Jiarong – sequence: 2 givenname: Man surname: Li fullname: Li, Man – sequence: 3 givenname: Shumei surname: Liang fullname: Liang, Shumei – sequence: 4 givenname: Yunchu surname: Yang fullname: Yang, Yunchu – sequence: 5 givenname: Jingfang surname: Wu fullname: Wu, Jingfang – sequence: 6 givenname: Qingqing surname: Zou fullname: Zou, Qingqing – sequence: 7 givenname: Shun surname: Fang fullname: Fang, Shun – sequence: 8 givenname: Size surname: Chen fullname: Chen, Size – sequence: 9 givenname: Linlang orcidid: 0000-0002-1859-7592 surname: Guo fullname: Guo, Linlang |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31118037$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kl1rFDEYhQep2A_9Ad7IgDd6MTXJTCaTG6EsfiwsCFavQyZ5M5Mym6xJptp_b6Zba7eI5CIvyXNOyOGcFkfOOyiKlxidY9y17yImnKAKYV4hmgf-pDjBjNKqY7w5ejAfF6cxXiHUIsrxs-K4xlmPanZSmLVLMASZQJejHcYqjcHPw7ibUymdnG6ijaXV4JI1FmIZ5x2EEtwonYIQSxmjV_ZW_tOmsVQjbH2ArEoLUVpXXq42q-fFUyOnCC_u9rPi-8cP31afq82XT-vVxaZSlDepwrRtNO5qhgk2TPKuN7ViYChHsgfSddAbxWtDgPW454rSXjLdS05Uo4CZ-qxY7321l1diF-xWhhvhpRW3Bz4MQoZk1QSC1pJQIrOTZA3leUIaal0z3bGclM5e7_deu7nfglY5gyCnA9PDG2dHMfhr0dKaEEqzwZs7g-B_zBCT2NqoYJqkAz9HQUhNMGpJQzL6-hF65eeQ81-ohjDKOMZ_qUHmD1hnfH5XLabignZtrgClXabO_0HlpWFrVW6Qsfn8QPD2QJCZBL_SIOcYxfry6yH76mEo92n8aVQG8B5QwccYwNwjGImltWLfWpFbK5bWCp417JFG2SST9UuudvqP8jekNvB4 |
CitedBy_id | crossref_primary_10_1038_s42003_025_07804_7 crossref_primary_10_3390_ijms23169154 crossref_primary_10_1371_journal_ppat_1009311 crossref_primary_10_1002_advs_202409050 crossref_primary_10_1016_j_celrep_2021_110109 crossref_primary_10_1002_1878_0261_12693 crossref_primary_10_3389_fphar_2022_1071365 crossref_primary_10_1016_j_canlet_2024_217129 crossref_primary_10_1089_gtmb_2023_0280 crossref_primary_10_1016_j_mam_2023_101205 crossref_primary_10_3390_cancers14081978 crossref_primary_10_1016_j_celrep_2020_107532 |
Cites_doi | 10.1016/j.cell.2016.12.013 10.1038/nrg3496 10.1146/annurev.genet.37.110801.143851 10.1186/gb-2008-9-9-r137 10.18632/oncotarget.11057 10.1016/S0140-6736(11)60165-7 10.1016/j.cell.2013.03.035 10.1038/s41467-018-03279-9 10.1016/j.cell.2013.02.014 10.1016/j.trecan.2017.03.006 10.1186/1476-4598-6-31 10.1126/science.aar3958 10.2174/1566524016666151222144656 10.1038/s41568-018-0005-8 10.1093/bioinformatics/btn542 10.1038/nm.3665 10.1038/ng.3167 10.1016/j.cell.2014.02.009 10.1126/scisignal.2001946 10.1038/ng.3605 10.1016/j.leukres.2011.08.006 10.1016/j.cub.2010.06.070 10.1016/j.cell.2013.03.036 10.1016/j.cell.2013.09.053 10.1158/0008-5472.CAN-16-2874 10.1038/onc.2012.306 10.1016/j.ccell.2018.03.022 10.1186/gb-2007-8-2-r24 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7X7 7XB 88E 8AO 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 5PM DOA |
DOI | 10.1186/s12920-019-0520-9 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (subscription) ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1755-8794 |
EndPage | 12 |
ExternalDocumentID | oai_doaj_org_article_53a252ae7ba74592ae0de3d37d87006d PMC6532255 A586520558 31118037 10_1186_s12920_019_0520_9 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; grantid: 81772458 – fundername: ; grantid: 81572244 – fundername: ; grantid: 2015A030311028 – fundername: ; grantid: 2017A030313468 |
GroupedDBID | --- 0R~ 23N 2WC 53G 5GY 5VS 6J9 7X7 88E 8AO 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR INH INR ISR ITC KQ8 LK8 M1P M48 M7P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D ~8M -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ K9. P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c594t-1564d1837121f7a98bf3c7ef590abe288ebfc93f2e7b1b9c55ba7dba92c4ce7f3 |
IEDL.DBID | 7X7 |
ISSN | 1755-8794 |
IngestDate | Wed Aug 27 01:32:12 EDT 2025 Thu Aug 21 14:11:46 EDT 2025 Fri Jul 11 14:13:14 EDT 2025 Fri Jul 25 19:22:12 EDT 2025 Tue Jun 17 21:06:09 EDT 2025 Tue Jun 10 20:29:15 EDT 2025 Fri Jun 27 04:59:05 EDT 2025 Thu Jan 02 22:59:27 EST 2025 Tue Jul 01 02:55:34 EDT 2025 Thu Apr 24 22:51:55 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Small cell lung cancer Chemoresistance Super enhancer |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c594t-1564d1837121f7a98bf3c7ef590abe288ebfc93f2e7b1b9c55ba7dba92c4ce7f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0002-1859-7592 |
OpenAccessLink | https://www.proquest.com/docview/2242757911?pq-origsite=%requestingapplication% |
PMID | 31118037 |
PQID | 2242757911 |
PQPubID | 55237 |
PageCount | 12 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_53a252ae7ba74592ae0de3d37d87006d pubmedcentral_primary_oai_pubmedcentral_nih_gov_6532255 proquest_miscellaneous_2232106242 proquest_journals_2242757911 gale_infotracmisc_A586520558 gale_infotracacademiconefile_A586520558 gale_incontextgauss_ISR_A586520558 pubmed_primary_31118037 crossref_primary_10_1186_s12920_019_0520_9 crossref_citationtrail_10_1186_s12920_019_0520_9 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2019-05-22 |
PublicationDateYYYYMMDD | 2019-05-22 |
PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-22 day: 22 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC medical genomics |
PublicationTitleAlternate | BMC Med Genomics |
PublicationYear | 2019 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | J Tower (520_CR2) 2004; 38 SC Tripathi (520_CR13) 2017; 77 JE Bradner (520_CR27) 2017; 168 L Adesso (520_CR28) 2013; 32 J Hu (520_CR29) 2016; 16 M Corvaisier (520_CR20) 2016; 7 M Levine (520_CR26) 2010; 20 TS Huang (520_CR21) 2007; 6 HY Shin (520_CR8) 2018; 41 JP van Meerbeeck (520_CR1) 2011; 378 D Hay (520_CR17) 2016; 48 D Herranz (520_CR5) 2014; 20 M Levine (520_CR25) 2014; 157 RW Robey (520_CR14) 2018; 18 WA Whyte (520_CR23) 2013; 153 A Kuhnl (520_CR22) 2011; 35 J Lovén (520_CR7) 2013; 153 Y Zhang (520_CR10) 2008; 9 M Rojo de la Vega (520_CR12) 2018; 34 D Hnisz (520_CR3) 2013; 155 S Pott (520_CR4) 2015; 47 S Sengupta (520_CR15) 2017; 3 H Stower (520_CR9) 2013; 14 J Huang (520_CR16) 2018; 9 A Brozzi (520_CR11) 2008; 24 TI Lee (520_CR24) 2013; 152 S Gupta (520_CR18) 2007; 8 BR Sabari (520_CR6) 2018; 361 S Ganesan (520_CR19) 2011; 4 |
References_xml | – volume: 168 start-page: 629 issue: 4 year: 2017 ident: 520_CR27 publication-title: Cell doi: 10.1016/j.cell.2016.12.013 – volume: 14 start-page: 367 issue: 6 year: 2013 ident: 520_CR9 publication-title: Nat Rev Genet doi: 10.1038/nrg3496 – volume: 38 start-page: 273 year: 2004 ident: 520_CR2 publication-title: Annu Rev Genet doi: 10.1146/annurev.genet.37.110801.143851 – volume: 9 start-page: R137 issue: 9 year: 2008 ident: 520_CR10 publication-title: Genome Biol doi: 10.1186/gb-2008-9-9-r137 – volume: 7 start-page: 56699 issue: 35 year: 2016 ident: 520_CR20 publication-title: Oncotarget doi: 10.18632/oncotarget.11057 – volume: 378 start-page: 1741 issue: 9804 year: 2011 ident: 520_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(11)60165-7 – volume: 153 start-page: 307 issue: 2 year: 2013 ident: 520_CR23 publication-title: Cell doi: 10.1016/j.cell.2013.03.035 – volume: 9 start-page: 943 issue: 1 year: 2018 ident: 520_CR16 publication-title: Nat Commun doi: 10.1038/s41467-018-03279-9 – volume: 152 start-page: 1237 issue: 6 year: 2013 ident: 520_CR24 publication-title: Cell doi: 10.1016/j.cell.2013.02.014 – volume: 3 start-page: 269 issue: 4 year: 2017 ident: 520_CR15 publication-title: Trends Cancer doi: 10.1016/j.trecan.2017.03.006 – volume: 6 start-page: 31 year: 2007 ident: 520_CR21 publication-title: Mol Cancer doi: 10.1186/1476-4598-6-31 – volume: 41 start-page: 506 issue: 6 year: 2018 ident: 520_CR8 publication-title: Mol Cell – volume: 361 start-page: eaar3958 issue: 6400 year: 2018 ident: 520_CR6 publication-title: Science (New York, NY) doi: 10.1126/science.aar3958 – volume: 16 start-page: 70 issue: 1 year: 2016 ident: 520_CR29 publication-title: Curr Mol Med doi: 10.2174/1566524016666151222144656 – volume: 18 start-page: 452 issue: 7 year: 2018 ident: 520_CR14 publication-title: Nat Rev Cancer doi: 10.1038/s41568-018-0005-8 – volume: 24 start-page: 2918 issue: 24 year: 2008 ident: 520_CR11 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btn542 – volume: 20 start-page: 1130 issue: 10 year: 2014 ident: 520_CR5 publication-title: Nat Med doi: 10.1038/nm.3665 – volume: 47 start-page: 8 issue: 1 year: 2015 ident: 520_CR4 publication-title: Nat Genet doi: 10.1038/ng.3167 – volume: 157 start-page: 13 issue: 1 year: 2014 ident: 520_CR25 publication-title: Cell doi: 10.1016/j.cell.2014.02.009 – volume: 4 start-page: pe15 issue: 166 year: 2011 ident: 520_CR19 publication-title: Sci Signal doi: 10.1126/scisignal.2001946 – volume: 48 start-page: 895 issue: 8 year: 2016 ident: 520_CR17 publication-title: Nat Genet doi: 10.1038/ng.3605 – volume: 35 start-page: 1585 issue: 12 year: 2011 ident: 520_CR22 publication-title: Leuk Res doi: 10.1016/j.leukres.2011.08.006 – volume: 20 start-page: R754 issue: 17 year: 2010 ident: 520_CR26 publication-title: Curr Biol doi: 10.1016/j.cub.2010.06.070 – volume: 153 start-page: 320 issue: 2 year: 2013 ident: 520_CR7 publication-title: Cell doi: 10.1016/j.cell.2013.03.036 – volume: 155 start-page: 934 issue: 4 year: 2013 ident: 520_CR3 publication-title: Cell doi: 10.1016/j.cell.2013.09.053 – volume: 77 start-page: 4414 issue: 16 year: 2017 ident: 520_CR13 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-2874 – volume: 32 start-page: 2848 issue: 23 year: 2013 ident: 520_CR28 publication-title: Oncogene doi: 10.1038/onc.2012.306 – volume: 34 start-page: 21 issue: 1 year: 2018 ident: 520_CR12 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.03.022 – volume: 8 start-page: R24 issue: 2 year: 2007 ident: 520_CR18 publication-title: Genome Biol doi: 10.1186/gb-2007-8-2-r24 |
SSID | ssj0060591 |
Score | 2.283357 |
Snippet | Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super enhancer (SE)... Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by super... Abstract Background Chemoresistance is a primary clinical challenge for the management of small cell lung cancer. Additionally, transcriptional regulation by... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 67 |
SubjectTerms | Analysis Bioinformatics Biological response modifiers Cancer Cancer research Cancer therapies Care and treatment Cell Line, Tumor Chemoresistance Chemotherapy Chromatin Computational Biology CRISPR-Cas technology Deoxyribonucleic acid Disease DNA Drug resistance Drug Resistance, Neoplasm - genetics Enhancer Elements, Genetic - genetics Enhancers Forkhead protein Foxp1 protein Gene amplification Gene expression Gene regulation Genetic aspects Genomes High-Throughput Nucleotide Sequencing High-throughput screening (Biochemical assaying) Humans Immunoprecipitation Interferon Interferon regulatory factor Interferon regulatory factor 1 Leukemia Lung cancer Lung Neoplasms - genetics Lung Neoplasms - pathology Noncoding DNA Polymerase chain reaction Regulatory sequences Reverse transcription RNA RNA interference RNA polymerase RNA sequencing RNA-mediated interference Sequence Analysis, RNA Small cell lung cancer Small cell lung carcinoma Small Cell Lung Carcinoma - genetics Small Cell Lung Carcinoma - pathology Sp1 protein Super enhancer Therapeutic applications Transcription (Genetics) Transcription factors Transcription Factors - metabolism Tumors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA9yD-KL-G31lCiCIIRr06RJHs_F4048HzwP7i2k-fAWju6y3f7_zrTZZYugL76VzYS285vMTLaT3xDyIYWoJPcVM9o5JkyEq0YaFkLrghI-ifFQ2OX35vxafL2RNwetvrAmbKIHnhR3ImvHJXdRtU4JaeCqDLEOtQpgaWUT0PtCzNttpiYfDDm6qfI3zEo3J32FTZlg22wY1n0wM4tCI1n_ny75ICbN6yUPAtDZI_IwZ470dHrix-Re7J6Q-5f52_hTki52zA-BIgkxyy141sOWukw9Qpdhqg6KPe2HddzQ2N0i7pueugwUTMc_ZymgiUW4PSaYIEGXHb1afFs8I9dnX34uzlnuosC8NGLLkA0mwMJVFa-Scka3qfYqJmlK10audWyTN3XioOKqNV5K0DQgZbgXPqpUPydH3aqLLwkNrRTRlalxtRC-CaaM2slkTIypTaIsSLnTqvWZYhw7XdzZcauhGzsBYQEIi0BYU5BP-ynriV_jb8KfEaq9IFJjjz-AwdhsMPZfBlOQ9wi0RfKLDqtrfrmh7-3F1Q97KnUDN5JSF-RjFkoreAPv8mEF0APyZc0kj2eSsDr9fHhnTzZ7h95C2sSVVBBnCvJuP4wzseKti6sBZfB0FZ7eKciLyfz2711XSNxXq4KomWHOFDMf6Za3I3d4I9GDy1f_Q5OvyQM-LSnG-TE52m6G-AZStG37dlyNvwFVpzpc priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA_nCeKL-G31lCiCIFTbNGmaB5Fz8bgT1wfPhXsLaT7uFo7uut0F_e-dadNyxePeymZCm_xmMpPN5DeEvA3OS8FsnqrKmJQrD0-lUKlztXGS28C7S2HzH-Xxgn87E2d7ZChvFSewvXZrh_WkFpvLD39-__0MBv-pM_iq_NjmWHIJNsUqxayOVN0it8ExSbTTOR8PFSBwV3k82Ly228Q1dQz-_6_TVxzVNInyilc6uk_uxXCSHvb4PyB7vnlI7szjgfkjEk4GOghHkZk4jXV51rstNZGPhC5dnzLkW9ru1n5DfXOByrBpqYnoQXf8x5YCxJiZ22LUCRJ02dDT2ffZY7I4-vprdpzG0gqpFYpvU6SIcWDNMmd5kEZVdSis9EGozNSeVZWvg1VFYF7Wea2sELWRAJ9illsvQ_GE7Derxj8j1NWCe5OF0hSc29KpzFdGBKW8D3XgWUKyYVa1jbzjWP7iUnf7j6rUPRAagNAIhFYJeT92WfekGzcJf0GoRkHky-5-WG3OdTQ_LQrDBDMwGiO5UPCUOV-4QjpYr7LSJeQNAq2REaPBlJtzs2tbfXL6Ux-KqoQXCVEl5F0UCisYgTXxBgPMA5JoTSQPJpJgsnbaPOiTHjReQyzFpJDgfBLyemzGnpgG1_jVDmXwyhVe6UnI0179xnEXObL5FTIhcqKYk4mZtjTLi45QvBS4rIvnN3_WC3KX9caSMnZA9rebnX8JEdm2ftXZ2T8okjTG priority: 102 providerName: Scholars Portal |
Title | Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC |
URI | https://www.ncbi.nlm.nih.gov/pubmed/31118037 https://www.proquest.com/docview/2242757911 https://www.proquest.com/docview/2232106242 https://pubmed.ncbi.nlm.nih.gov/PMC6532255 https://doaj.org/article/53a252ae7ba74592ae0de3d37d87006d |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZbC2MvY_e564I2BoOBqC1LlvU00tDShqWMZoW8CVmXNjCcLI7_f3VsJasZ9MU21hG29Okc3Y6-g9BXb53g1GRElloTJl14Krgk1lbaCmY86w6Fza6Kixs2XfBFXHBrolvlziZ2htquDKyRn4Suhgougm7-WP8lEDUKdldjCI2n6BCoy8ClSyz2E64wUpdZ3MnMyuKkySA0U5g8SwLeH0QO-qKOsv9_w_ygZxp6TT7ohs5fohdx_IjHPeCv0BNXv0bPZnGH_A3ylzv-B4uBipjEQDzrdot1JCDBS9v7CLkGN-3abbCr7wD9TYN1hCtkhyVaHDAFV9wGhplBAi9rPJ_8nLxFN-dnvycXJMZSIIZLtiXACWOD-oqMZl5oWVY-N8J5LlNdOVqWrvJG5p46UWWVNJxXWgS8JDXMOOHzd-igXtXuA8K24szp1Bc6Z8wUVqau1NxL6ZyvPEsTlO5qVZlINA7xLv6obsJRFqoHQgUgFAChZIK-77Ose5aNx4RPAaq9IBBkdy9Wm1sV9U3xXFNOdSiNFozL8JRal9tc2GCg0sIm6AsArYACowYfm1vdNo26nF-rMS-L8CHOywR9i0J-FUpgdDyyEOoBWLMGkscDyaCjZpi8a08q2ohG_WvRCfq8T4ac4PdWu1ULMnDGCs7wJOh93_z25c4zoO_LRYLEoGEOKmaYUi_vOgbxgoMd50eP_9ZH9Jz2ykIoPUYH203rPoUh2LYadXo2Qofj8XQ-DffTs6tf16NuQSNcZ6y8ByTcNsg |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJwEviDuBAQaBkJCiJY4dxw8IbWVTy9oK7SLtzTi-bJVQWppWiD_Fb8SnccoipL3tLYqPk9jn5hMffwehd85YzohOY1EoFVNh_VXORGxMqQyn2tH1obDxJB-c0a_n7HwL_WnPwkBaZWsT14bazDT8I9_1roZwxr1ufp7_jKFqFOyutiU0GrE4sr9_-ZCt_jT84vn7npDDg9P-IA5VBWLNBF3GgI5ivCDzlKSOK1GULtPcOiYSVVpSFLZ0WmSOWF6mpdCMlYr7LxdEU225y_xzb6FtmvlQpoe29w8m345b2-9jA5GGvdO0yHfrFIpB-XBdxJBvEouO91sXCfjfFVzxhd08zSuO7_A-uhdWrHivEbEHaMtWD9HtcdiTf4TcsEWcMBjAj-NQ-me-WmIVIE_w1DRZSbbG9WpuF9hWlyBvixqrICC-O_wUxl6KIPm3hoWtp8DTCp_0R_3H6OxG5vkJ6lWzyj5D2JSMWpW4XGWU6tyIxBaKOSGsdaWjSYSSdlalDtDmUGHjh1yHOEUuG0ZIzwgJjJAiQh83XeYNrsd1xPvAqg0hQHKvb8wWFzJouGSZIowoPxrFKRP-KjE2Mxk33iQmuYnQW2C0BNCNCrJ6LtSqruXw5FjusSL3L2KsiNCHQORmfgRahUMSfh4Ap6tDudOh9FZBd5tbeZLBKtXynw5F6M2mGXpCpl1lZyuggVNdcGooQk8b8duMO0sBMDDjEeIdwexMTLelml6uMctzBp6DPb_-s16jO4PT8UiOhpOjF-guaRQnJmQH9ZaLlX3pF4DL8lXQOoy-37Si_wXNs3Hk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Integrated+high-throughput+analysis+identifies+super+enhancers+associated+with+chemoresistance+in+SCLC&rft.jtitle=BMC+medical+genomics&rft.au=Bao%2C+Jiarong&rft.au=Li%2C+Man&rft.au=Liang%2C+Shumei&rft.au=Yang%2C+Yunchu&rft.date=2019-05-22&rft.pub=BioMed+Central&rft.eissn=1755-8794&rft.volume=12&rft_id=info:doi/10.1186%2Fs12920-019-0520-9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1755-8794&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1755-8794&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1755-8794&client=summon |